^
Association details:
| Biomarker: | KRAS mutation |
|---|---|
| Cancer: | Endometrial Cancer |
| Drug: | lifirafenib (BGB-283) (EGFR inhibitor, pan-RAF inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Phase I, Open-Label, Dose-Escalation/Dose-Expansion Study of Lifirafenib (BGB-283), an RAF Family Kinase Inhibitor, in Patients With Solid Tumors
Published date:
03/17/2020
Excerpt:
Patients with K-RAS-mutated endometrial cancer and K-RAS codon 12-mutated NSCLC had confirmed PR (n = 1 each).
DOI:
10.1200/JCO.19.02654
